Shou J - Search Results

1

Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R. Creighton CJ, et al. Among authors: shou j. Cancer Res. 2008 Sep 15;68(18):7493-501. doi: 10.1158/0008-5472.CAN-08-1404. Cancer Res. 2008. PMID: 18794137 Free PMC article.

2

Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Schiff R, Massarweh S, Shou J, Osborne CK. Schiff R, et al. Among authors: shou j. Clin Cancer Res. 2003 Jan;9(1 Pt 2):447S-54S. Clin Cancer Res. 2003. PMID: 12538499 Review.

3

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.

Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Schiff R, et al. Among authors: shou j. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):331S-6S. doi: 10.1158/1078-0432.ccr-031212. Clin Cancer Res. 2004. PMID: 14734488

4

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Shou J, et al. J Natl Cancer Inst. 2004 Jun 16;96(12):926-35. doi: 10.1093/jnci/djh166. J Natl Cancer Inst. 2004. PMID: 15199112

5

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.

Osborne CK, Shou J, Massarweh S, Schiff R. Osborne CK, et al. Among authors: shou j. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):865s-70s. Clin Cancer Res. 2005. PMID: 15701879 Review.

6

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Gutierrez MC, et al. Among authors: shou j. J Clin Oncol. 2005 Apr 10;23(11):2469-76. doi: 10.1200/JCO.2005.01.172. Epub 2005 Mar 7. J Clin Oncol. 2005. PMID: 15753463

7

Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.

Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Schiff R, et al. Among authors: shou j. Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:10-20. doi: 10.1007/s00280-005-0108-2. Cancer Chemother Pharmacol. 2005. PMID: 16273359 Review.

8

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.

Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. Huang C, et al. Among authors: shou j. Breast Cancer Res. 2011 Aug 31;13(4):R84. doi: 10.1186/bcr2936. Breast Cancer Res. 2011. PMID: 21884573 Free PMC article.

9

Estrogen receptor: current understanding of its activation and modulation.

Osborne CK, Schiff R, Fuqua SA, Shou J. Osborne CK, et al. Among authors: shou j. Clin Cancer Res. 2001 Dec;7(12 Suppl):4338s-4342s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916222 Review.

10

Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.

Dowsett M, Johnston S, Martin LA, Salter J, Hills M, Detre S, Gutierrez MC, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Smith I. Dowsett M, et al. Among authors: shou j. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S113-7. doi: 10.1677/erc.1.01044. Endocr Relat Cancer. 2005. PMID: 16113087 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

432 results

Search Page

Filters